What is Onpattro (patisiran), and how does “RNA seq” relate to it?
Onpattro is an RNA-based medicine (an siRNA) developed to treat hereditary transthyretin (hATTR) amyloidosis with polyneuropathy. “RNA seq” usually refers to RNA sequencing, but it can also be used loosely by people to mean “RNA” in general. Onpattro itself is not an RNA sequencing test; it delivers a specific RNA interference (siRNA) molecule to reduce production of a target protein involved in disease pathology.[1]
How does Onpattro work (siRNA/RNA interference)?
Onpattro uses small interfering RNA (siRNA) to silence the gene for transthyretin in the liver, lowering the amount of transthyretin protein that drives amyloid deposits. This is an RNA interference mechanism, not gene editing and not sequencing.[1]
Where does RNA sequencing come in for Onpattro patients?
RNA sequencing is a laboratory method used to measure gene expression patterns. Clinicians and researchers might use RNA sequencing to study:
- How disease-related genes and pathways behave in patients with hATTR amyloidosis
- Whether gene-expression signatures change with treatment
- Potential biomarkers related to response or progression
That kind of work is separate from Onpattro’s mechanism and dosing, and it is not required to receive the drug.[1]
Is Onpattro a “next-generation sequencing” (NGS) therapy?
No. Onpattro is a therapy that delivers siRNA into the body. RNA sequencing (including “RNA-seq”/NGS) is a diagnostic/research tool, while Onpattro is a medication. Confusing these terms is common because both involve RNA.[1]
Patents and exclusivity: where to check drug-specific IP details
If you meant “RNA seq” as in “patent / drug lifecycle” research around an RNA-based medicine like Onpattro, DrugPatentWatch.com is one place to look for timeline and patent-status information for specific products.[2]
---
Sources
- https://www.drugs.com/onpattro.html
- https://www.drugpatentwatch.com/